QuantHealth Releases Outcomes Showing $215M in Financial Returns and 85% Accuracy for Pharmaceutical Organizations

The Company Has Surpassed 100 Successfully Simulated Clinical Trials, Proven to Accelerate Trial Timelines and Improve Operational Efficiency

QuantHealth, an AI-powered clinical trial design company, announced it has surpassed 100 successfully simulated clinical trials, achieving 85 percent accuracy and significant return on investment (ROI) for pharmaceutical partners. The company leverages proprietary technology and patient-centric solutions to resolve the pervasive issue of trial failures. Historically, 90 percent of clinical trials fail due to suboptimal protocol design, inefficiencies, and safety concerns. With drug development taking 10 to 15 years and costing nearly $1 billion per drug, most candidates fail to reach approval. To address these challenges, QuantHealth's Clinical-Simulator forecasts individual patient responses within clinical trials, enabling design teams to anticipate overall trial dynamics and adjust strategies accordingly.

In partnership with one pharmaceutical company’s respiratory disease team, QuantHealth enabled cost reductions of more than $215M and significantly improved the likelihood of trial success. Harnessing data from 350M patients and 700,000 drug entities, its advanced analytics module simulated more than 5,000 protocol variations within minutes to identify which factors were most likely to contribute to success. Out of more than 30 positive protocols, it then determined the protocol that suggested the highest odds of technical success. Through this process, QuantHealth reduced study duration by 11 months, clinical trial subjects by 251 and full-time employees by 1.5 individuals, resulting in financial returns of $15M, $200M, and $385,000 respectively.

“Being at the forefront of AI-enabled clinical trials for nearly a decade, it’s astounding to see how much progress has been made and the promise that AI holds for clinical trial improvement,” said Orr Inbar, CEO and Co-Founder of QuantHealth. “Once seen as science fiction, our technology has proven to safely and accurately predict the results of clinical trials and now has significant traction. We currently have five of the top 20 pharmaceutical companies on board, and with this number expected to double by next year, we look forward to addressing the core issue of trial failures at scale, and continuing to meet market needs swiftly and effectively.”

QuantHealth’s accuracy outcomes exceeded national averages for Phase II and III, underlining the power of AI-generated clinical trials.

Accuracy by Therapeutic Area

• 58.3 percent better Oncology rates - 88 percent compared to the national rate of 29.7 percent
• 37.8 percent better Immune & Inflammation rates - 80 percent compared to the national rate of 42.2 percent
• 41.4 percent better Gastroenterology rates - 83 percent compared to the national rate of 41.6 percent
• 52.6 percent better Respiratory rates - 84 percent compared to the national rate of 31.4 percent

Accuracy by Trial Phase

• 59.1 percent better Phase 2 rates - 88 percent compared to the national rate of 28.9 percent
• 25.4 percent better Phase 3 rates - 83.2 percent compared to the national rate of 57.8 percent

QuantHealth employs a rigorous validation process encompassing logical, mathematical, clinical, and real-world validations. Its Clinical-Simulator runs thousands of protocols at scale, supporting development from target identification through to regulatory approval. QuantHealth partners closely with customers at every stage of the clinical trial journey—from pre-clinical to early and late-stage clinical trials—empowering them to make informed decisions and maximize therapeutic success. By empowering trial design teams to preemptively gauge and calibrate trial dynamics, QuantHealth paves a path towards enhanced outcomes and a blueprint for mitigating clinical trial setbacks.

About QuantHealth:

90% of drugs fail the clinical stage, representing a direct $45B annual waste to pharma companies. To address this challenge at its core, QuantHealth's Clinical-Simulator predicts how each patient in a clinical trial will respond to treatment, allowing trial design teams to predict how an entire clinical trial will play out and adapt accordingly. Based on its novel AI engine and a vast dataset of 350m patients and over 700K therapeutics, QuantHealth's simulator can predict clinical trial results with high accuracy, allowing users to answer mission-critical questions such as trial go/no-go, cohort optimization, drug repurposing, and more. QuantHealth was founded by healthcare experts who led commercial, product, and data science at various leading companies in the US and Israel. QuantHealth is backed by expert Life-Science investors in the US, Europe, and Israel and is supported by an advisory board of physicians and scientists from leading academic institutions. To learn more, visit https://quanthealth.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240820324274/en/